To that end, we evaluated the combination of an approved MEK inhibitor undergoing clinical trials in kidney cancer (cobimetinib50: NCT03264066) with cabozantinib in 2 VHL WT NCCRCC cells (ACHN and SN12C). This evidence concerns the gene MAP2K7 and kidney cancer.